Filing summary
Company identification: The supplied filing is Mast Therapeutics, Inc.’s Form 10-Q, not a Savara Inc. filing. It covers the quarter ended March 31, 2016; financial statements are unaudited.
Business context and reporting period
Mast was a clinical-stage biopharmaceutical company developing vepoloxamer for sickle cell disease and heart failure, and AIR001 for heart failure with preserved ejection fraction (HFpEF). It had no product sales or significant revenue and relied on financing to fund operations.
Financial results and position
| Metric | Q1 2016 | Q1 2015 / prior period |
|---|---|---|
| Revenue | $0 | $0 |
| R&D expense | $7.9 million | $6.0 million |
| SG&A expense | $2.8 million | $3.6 million |
| Total operating expenses | $10.7 million | $9.7 million |
| Operating loss | $10.7 million | $9.7 million |
| Net loss | $11.2 million | $9.6 million |
| Basic and diluted loss per share | $0.06 | $0.06 |
| Net cash used in operations | $11.3 million | $7.3 million |
At March 31, 2016, cash and cash equivalents were $23.5 million and investment securities were $13.6 million, totaling $37.1 million; working capital was $15.6 million. Total assets were $50.1 million, total liabilities $29.5 million, and stockholders’ equity $20.7 million. Debt facility carrying value was $14.8 million, including $11.4 million current and $3.4 million long-term. No gross margin is applicable because the company had no revenue.
Cash increased $0.5 million during the quarter: $11.3 million used in operations was offset by $4.4 million from investment maturities and $7.4 million from financing. The February public offering generated approximately $7.3 million net proceeds.
Material changes versus the prior comparable period
- R&D expense rose 30% year over year, mainly reflecting vepoloxamer clinical work, manufacturing, and NDA-preparation costs.
- SG&A fell 21%; Q1 2015 included severance and accelerated stock-compensation expense related to a former executive.
- Net loss increased by $1.6 million, and operating cash use increased by $4.0 million.
- Interest expense was $0.5 million in Q1 2016, primarily from the debt facility; none was reported in Q1 2015.
- Shares outstanding increased to 192.8 million at quarter-end from 163.6 million at December 31, 2015, following equity issuance.
Outlook, commentary, and key risks
- Management expected top-line results from the 388-patient Phase 3 EPIC sickle-cell study in Q2 2016. It had completed enrollment in February.
- If EPIC results supported an NDA, management projected $30–$33 million of operating expenses for the remaining nine months of 2016, excluding share-based compensation. It outlined a possible rolling NDA submission beginning in Q4 2016, subject to positive results and FDA feedback.
- Management said current resources were insufficient for planned operations over the next 12 months and disclosed substantial doubt about the company’s ability to continue as a going concern. It intended to seek additional capital before Q4 2016 through equity, debt, or collaborations; availability and terms were uncertain.
- Unless positive EPIC results were demonstrated to the lender by July 31, 2016, the company was required to prepay $10 million of debt. The debt agreement also restricted additional borrowing without lender consent. If financing failed or EPIC results were negative, management planned significant operating cuts; it estimated resources could support reduced operations into Q1 2017.
- A Phase 2a AIR001 study in 30 HFpEF patients reported positive top-line results in February 2016; the filing said the study met its primary endpoint and AIR001 was generally well tolerated. A separate approximately 100-patient study was expected to begin in Q3 2016.
- Material uncertainties included EPIC efficacy results, potential FDA requirements for additional studies or manufacturing controls, financing access, clinical and regulatory execution, and possible impairment of goodwill and in-process R&D.
Important facts for investors to verify
- Confirm the issuer: this filing identifies Mast Therapeutics, Inc., not Savara Inc.
- Review the subsequent EPIC Phase 3 results and the company’s related FDA/NDA plans.
- Check whether the $10 million debt prepayment condition was met and how the debt terms or maturity changed.
- Verify subsequent financing, cash runway, and whether management implemented the stated contingency cuts.
- Assess the status of AIR001 studies and any later updates to clinical, regulatory, or impairment risks.